D. Schwarck-Kokarakis

Abstract CT034: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent melanoma immunotherapy

J. Utikal, U. Şahin, M. Diken, 2017 .

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

J. Utikal, Ö. Türeci, U. Şahin, 2020, Nature.

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

J. Utikal, Ö. Türeci, U. Şahin, 2020, Nature.

A shared tumor-antigen RNA-lipoplex vaccine with/without anti-PD1 in patients with checkpoint-inhibition experienced melanoma.

J. Utikal, Ö. Türeci, U. Şahin, 2020 .

A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma.

J. Utikal, M. Gaiser, Ö. Türeci, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract CT032: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients with malignant melanoma

J. Utikal, U. Şahin, M. Diken, 2016 .

Abstract CT156: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma

J. Utikal, D. Jäger, Ö. Türeci, 2018, Clinical Trials.